377 related articles for article (PubMed ID: 26582456)
1. Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson's disease genetically related mutants.
Tosatto L; Horrocks MH; Dear AJ; Knowles TP; Dalla Serra M; Cremades N; Dobson CM; Klenerman D
Sci Rep; 2015 Nov; 5():16696. PubMed ID: 26582456
[TBL] [Abstract][Full Text] [Related]
2. Oligomers of Parkinson's Disease-Related α-Synuclein Mutants Have Similar Structures but Distinctive Membrane Permeabilization Properties.
Stefanovic AN; Lindhoud S; Semerdzhiev SA; Claessens MM; Subramaniam V
Biochemistry; 2015 May; 54(20):3142-50. PubMed ID: 25909158
[TBL] [Abstract][Full Text] [Related]
3. Familial Parkinson disease mutations influence α-synuclein assembly.
Ono K; Ikeda T; Takasaki J; Yamada M
Neurobiol Dis; 2011 Sep; 43(3):715-24. PubMed ID: 21684335
[TBL] [Abstract][Full Text] [Related]
4. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
Kumar S; Sarkar A; Sundar D
Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
[TBL] [Abstract][Full Text] [Related]
5. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA; do Nascimento LA; Eliezer D; Follmer C
ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
[TBL] [Abstract][Full Text] [Related]
6. Unveiling a Selective Mechanism for the Inhibition of α-Synuclein Aggregation by β-Synuclein.
Leitao A; Bhumkar A; Hunter DJB; Gambin Y; Sierecki E
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364143
[TBL] [Abstract][Full Text] [Related]
7. Phase transitions and structure analysis in wild-type, A30P, E46K, and A53T mutants of α-synuclein.
Healey MA; Woodside MT; Tuszynski JA
Eur Biophys J; 2016 May; 45(4):355-64. PubMed ID: 26695014
[TBL] [Abstract][Full Text] [Related]
8. Structures and free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins with dynamics.
Wise-Scira O; Aloglu AK; Dunn A; Sakallioglu IT; Coskuner O
ACS Chem Neurosci; 2013 Mar; 4(3):486-97. PubMed ID: 23374072
[TBL] [Abstract][Full Text] [Related]
9. Structures of the E46K mutant-type α-synuclein protein and impact of E46K mutation on the structures of the wild-type α-synuclein protein.
Wise-Scira O; Dunn A; Aloglu AK; Sakallioglu IT; Coskuner O
ACS Chem Neurosci; 2013 Mar; 4(3):498-508. PubMed ID: 23374074
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions.
Tsigelny IF; Sharikov Y; Kouznetsova VL; Greenberg JP; Wrasidlo W; Overk C; Gonzalez T; Trejo M; Spencer B; Kosberg K; Masliah E
ACS Chem Neurosci; 2015 Mar; 6(3):403-16. PubMed ID: 25561023
[TBL] [Abstract][Full Text] [Related]
11. The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro.
Ghosh D; Mondal M; Mohite GM; Singh PK; Ranjan P; Anoop A; Ghosh S; Jha NN; Kumar A; Maji SK
Biochemistry; 2013 Oct; 52(40):6925-7. PubMed ID: 24047453
[TBL] [Abstract][Full Text] [Related]
12. Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein.
Kaylor J; Bodner N; Edridge S; Yamin G; Hong DP; Fink AL
J Mol Biol; 2005 Oct; 353(2):357-72. PubMed ID: 16171820
[TBL] [Abstract][Full Text] [Related]
13. Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics.
Coskuner O; Wise-Scira O
ACS Chem Neurosci; 2013 Jul; 4(7):1101-13. PubMed ID: 23607785
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
15. Formation and Characterization of α-Synuclein Oligomers.
Paslawski W; Lorenzen N; Otzen DE
Methods Mol Biol; 2016; 1345():133-50. PubMed ID: 26453210
[TBL] [Abstract][Full Text] [Related]
16. Label-free detection of early oligomerization of α-synuclein and its mutants A30P/E46K through solid-state nanopores.
Li X; Tong X; Lu W; Yu D; Diao J; Zhao Q
Nanoscale; 2019 Mar; 11(13):6480-6488. PubMed ID: 30892349
[TBL] [Abstract][Full Text] [Related]
17. Alpha synuclein dimers and oligomers are increased in overexpressing conditions in vitro and in vivo.
Marmolino D; Foerch P; Atienzar FA; Staelens L; Michel A; Scheller D
Mol Cell Neurosci; 2016 Mar; 71():92-101. PubMed ID: 26711807
[TBL] [Abstract][Full Text] [Related]
18. Co-existence of two different α-synuclein oligomers with different core structures determined by hydrogen/deuterium exchange mass spectrometry.
Paslawski W; Mysling S; Thomsen K; Jørgensen TJ; Otzen DE
Angew Chem Int Ed Engl; 2014 Jul; 53(29):7560-3. PubMed ID: 24740651
[TBL] [Abstract][Full Text] [Related]
19. Nanomolar oligomerization and selective co-aggregation of α-synuclein pathogenic mutants revealed by single-molecule fluorescence.
Sierecki E; Giles N; Bowden Q; Polinkovsky ME; Steinbeck J; Arrioti N; Rahman D; Bhumkar A; Nicovich PR; Ross I; Parton RG; Böcking T; Gambin Y
Sci Rep; 2016 Nov; 6():37630. PubMed ID: 27892477
[TBL] [Abstract][Full Text] [Related]
20. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
